11.08.2022 15:51

ivWatch Extends Its Global Reach Signing Three New Distribution Partners

Folgen
Werbung

Company Strengthens International Expansion and Broadens the Availability of Continuous IV Monitoring Solutions to Strategic Markets

NEWPORT NEWS, Va., Aug. 11, 2022 /PRNewswire/ -- Today, ivWatch, LLC, an innovative IV safety company working to eliminate harm caused by infiltration and extravasation events, announced three new strategic distribution partnerships internationally. Bameco in Austria, Warba Medical Supplies in Kuwait, and Mustafa Sultan Science & Industry Co, LLC in Oman have each signed exclusive agreements to promote, sell, and support ivWatch's continuous monitoring products in their markets. ivWatch's novel technologies will complement and bolster their existing portfolios of intravenous products provided to hospitals and other health care facilities.

ivWatch sensors use visible and near-infrared light to measure changes in the optical properties of the tissue near a peripheral IV insertion site. Audible and visual notifications are provided through a patient monitor when changes consistent with IV fluid leaking and pooling in the tissue adjacent to the IV site are detected.

ivWatch solutions continue to be available in more countries throughout the globe and with the addition of Austria, Kuwait, and Oman, clinicians will now be able to improve their bedside decision-making with real-time IV infiltration data. Continuous IV site monitoring provides accurate and precise insights to detect infiltrations and extravasations at their earliest stages. ivWatch's proprietary algorithm detects infiltrations promptly and notifies clinicians of adverse IV therapy events often hours before they are detectable by visual or tactile examination.1

"At ivWatch, we are on a steadfast mission to improve IV safety globally and we are extremely passionate about partnering with likeminded innovators who share that same relentless pursuit to advance patient safety," said Chuck Egress, Vice President of Business Development and Emerging Markets at ivWatch. "IV infiltrations and extravasations are a major global patient safety concern, and these new partnerships provide increased access to advanced safety solutions to help end complications and improve patient outcomes in IV therapy."

ivWatch has over 60 patents worldwide and received its first FDA clearance in 2015 for its IV site monitoring system that consists of an ivWatch Patient Monitor and a reusable optical biosensor that uses visible and near-infrared light to continuously measure changes in the optical properties of the tissue near an IV insertion site. In 2020, the company expanded its portfolio of sensor solutions and received FDA clearance for a single-use, miniaturized biosensor that is cleared for all patient age groups, sizes, and skin tones. Both sensors work seamlessly with the intuitive user interface on the Patient Monitor, which issues audible and visual "Check IV" alerts for the clinician to assess the IV site. ivWatch technology performs with high accuracy, intelligence, and low false alarm rates, which is critical to improving patient outcomes.

To learn more about ivWatch, visit www.ivWatch.com or follow the Company's social media platforms for the latest updates on new continuous monitoring innovations in IV safety. 

1 Doellman, D. and Rineair, S. (2019) The use of optical detection for continuous monitoring of pediatric IV sites. Journal of the Association for Vascular Access: Summer 2019, Vol. 24, No. 2, pp. 44-47.

About ivWatch, LLC
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. Our innovative continuous monitoring IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch, Facebook @ivWatchLLC, LinkedIn @ivWatch or visit www.ivWatch.com.

ivWatch, LLC (PRNewsfoto/ivWatch, LLC)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ivwatch-extends-its-global-reach-signing-three-new-distribution-partners-301604366.html

SOURCE ivWatch, LLC

Jetzt noch kostenlos für Donnerstag anmelden!

Wie sieht die Energie-Versorgung in der Zukunft aus? Im B2B-Seminar morgen um 11 Uhr erfahren Sie, welche Lösungen für die Energiekrise in Europa gefunden werden können und wie Sie mit Ihrem Portfolio an den Entwicklungen partizipieren!

Werbung
Werbung
Werbung
Neue Funktionen als Erstes nutzen
Sie nutzen finanzen.net regelmäßig? Dann nutzen Sie jetzt neue Funktionen als Erstes!
Hier informieren!
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

Rezessionsängste: DAX rutscht zeitweise unter 12.000 Punkte -- EU geht von Pipeline-Sabotage aus -- Apple mit schwächerer Nachfrage-- eBay, Biogen im Fokus

Credit Suisse verliert Top-Manager. Santander verkündet neues Rückkaufprogramm und zahlt Zwischendividende. IG Metall sieht schwierige Tarifverhandlungen mit VW kommen. SEC verhängt Wall Street-Unternehmen eine Milliardenstrafe. Vonovia will von Kündigungen bei Energiekosten-Not absehen. Lidl und Kaufland bitten bei E-Auto-Ladesäulen ab jetzt zur Kasse.

Umfrage

Sollte Deutschland Kampfpanzer und weitere schwere Waffen an die Ukraine zu liefern

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln